Date: 21-Sep-2020

Moderna And Chiesi Group Sign Agreement To Develop Treatment For Pulmonary Arterial Hypertension (PAH)

Moderna, Inc. a pioneering biotechnology company in therapies and vaccines through Messenger RNA (mRNA), and Chiesi Farmaceutici SpA, a healthcare group international research center ( Grupo Chiesi ), announce a collaboration aimed at the discovery and development of therapies through mRNA for the treatment of pulmonary arterial hypertension (PAH), a rare progressive disease characterized by hypertension in the arteries of the lungs with the development of insufficiency concomitant right heart disease. With the incidence of 2 to 5 people per million adults [1], PAH has generated an unmet medical need for new treatments that can delay or reverse the progression of the disease in patients.  

Messenger RNA (mRNA) is a ribonucleic acid responsible for guiding protein synthesis and carrying DNA information from the nucleus to the cytoplasm, where the protein will be produced. Present in all cells of the body, mRNA helps the body to produce the proteins necessary to treat and prevent disease.

Under the terms of the agreement, Moderna will lead the discovery efforts, leveraging its leading mRNA technology and delivery platforms along with Chiesi's experience in the field of HAP biology, while the Chiesi Group will conduct global development and commercialization activities and finance all collaboration related expenses. Moderna will receive $ 25 million in advance and is eligible for more than $ 400 million in development, regulatory and commercial actions, as well as double-digit royalties on net sales.

"We are excited to start this collaboration with the Chiesi Group , which offers the opportunity to further leverage our mRNA-related technology," said Stephen Hoge , MD, president of Moderna . "This new relationship continues our commitment to partner with companies that have outstanding experience in serious illnesses and that share our vision of using mRNA therapy to meet unmet needs of patients."

For Ugo Di Francesco , Executive Director of the Chiesi Group : "The Chiesi Group is at the forefront of innovation and the discovery of new therapies for people affected by diseases that have a high unmet medical need and the agreement with Moderna, leader in therapy through mRNA, confirms our commitment to better serve patients and healthcare professionals with transformative solutions ".